Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation
Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced a definitive agreement to acquire PathAI, a leading...
OTCMKTS: RHHBY
Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds
Roche AG (SWX: ROP, OTCMKTS: RHHBY) reported first-quarter 2026 group sales of CHF 14.7 billion...
Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials
Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that its investigational non-covalent Bruton’s tyrosine kinase (BTK)...
Roche’s Gazyva Gains FDA Review Acceptance for Systemic Lupus Erythematosus Treatment
Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration (FDA)...
Roche’s Elecsys NfL Test Gains CE Mark for Blood-Based Multiple Sclerosis Neuroinflammation Monitoring
Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced on 13 April 2026 that its Elecsys Neurofilament...
China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access
China Resources Pharmaceutical Commercial Group announced in early March 2026 a strategic cooperation agreement with...
C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology
C4 Therapeutics, Inc. (NASDAQ: CCCC), a leader in targeted protein degradation (TPD), announced an expanded...
Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety
Roche AG (SWX: ROG, OTCMKTS: RHHBY) has announced the commercial launch of its cobas MPX-E...
Roche Opens Institute of Human Biology – CHF 1.4 Billion Basel Investment Targets Human Model Systems for Drug Discovery Revolution
Roche (SWX: ROG, OTCMKTS: RHHBY) announced the inauguration of the new research home for the...
Roche Deploys 2,176 NVIDIA GPUs in Global AI Factory – Largest Pharma GPU Footprint Expands to 3,500+ Blackwell Units
Roche (SWX: ROG, OTCMKTS: RHHBY) announced the expansion of its global AI infrastructure through the...
Roche’s Petrelintide Hits 10.7% Weight Loss in Phase II ZUPREME-1 Trial – Amylin Analog Shows Sustained Efficacy Through Week 42
Roche (SWX: ROG, OTCMKTS: RHHBY) announced positive topline results from the Phase II ZUPREME-1 trial...
Roche’s Xofluza Wins NMPA Approval for Pediatric Expansion – Oral Suspension Cleared for Children Under 5 Years
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that Xofluza (baloxavir marboxil) has received expanded NMPA approval...
Roche’s Fenebrutinib Hits Phase III Endpoint in MS – BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the pivotal Phase III FENhance 1 study for fenebrutinib in relapsing...
SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal
SanegeneBio, a Suzhou‑based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a...
Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China
Roche (SWX: ROG, OTCMKTS: RHHBY) reported full‑year 2025 sales of CHF 61.5 billion : (USD 69.1 billion), representing 7% growth at...
Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial
Roche (SWX: ROG, OTCMKTS: RHHBY) announced positive topline results from its Phase II clinical trial (CT388‑103)...
MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal
MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY)...
Roche cobas-liat Whooping-Cough Test Secures FDA Clearance
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its cobas liat system-based point‑of‑care test for whooping...
Roche’s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma
Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted...
Roche’s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial
Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint...